RecruitingNANCT07368829

Feasibility and Safety of Artificial Intelligence-Driven Autonomous Registration in Robotic Navigational Bronchoscopy

Sponsor: Ruijin Hospital

Trial Details

Condition	Lung Nodules, Bronchoscopy, Localization Efficiency
Intervention	AI-driven autonomous registration
Phase	NA
Status	Recruiting
Participants	20
Est. Completion	30 June 2026
Last Updated	13 Apr 2026

Primary Outcome

Autonomous registration success rate; Manual intervention rate during autonomous registration

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria: * Age ≥ 18 years. * Radiologically confirmed pulmonary nodules requiring preoperative localization. * Scheduled for robotic navigational bronchoscopy using the Bronchoscopy Robot System. * Willing to provide written informed consent. Exclusion Criteria: * Severe cardiopulmonary dysfunction (e.g., FEV1 \< 30% predicted). * Coagulopathy or anticoagulation therapy that cannot be safely interrupted. * Pregnancy or lactation. * Inability to tolerate bronchoscopy under general anesthesia.

Trial Sites

Countries

China

View Registry Entry

Related Analysis

First-in-Human Trial Tests AI-Autonomous Registration in Robotic Bronchoscopy for Lung Nodule Localization — Early Safety Data Expected

First clinical trial testing AI-driven autonomous registration in robotic bronchoscopy launches in China, potentially eliminating operator dependency in lung nodule localization procedures. Early safety and feasibility data expected by 2026.

Read full article →

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service